Cure8 news brief
This study identifies a specific genetic cause (BIRC3 variants) that drives inflammation through the RIPK1/TNF pathway and points to an existing drug target (RIPK1). If validated, the finding could help match patients to more precise treatments and explain variable responses to anti-TNF drugs.
Clinicians and researchers working on IBD genetics and targeted therapies; patients (including pediatric and adult) with early-onset, familial, or treatment-resistant Crohn's disease who are interested in genetic evaluation; translational researchers and trialists focused on RIPK1 or TNF-pathway drugs.
BIRC3 variants were found to impair a protective function in intestinal cells and activate a RIPK1-related inflammatory route tied to TNF signaling. The researchers combined genetics, RNA sequencing and proteomics and developed animal models to trace how these variants cause gut inflammation.
The study expands the concept of monogenic IBD beyond very early childhood cases: some adults or familial cases may carry single-gene changes that meaningfully affect disease biology and treatment response.
The authors propose using these findings to better predict who may or may not respond to anti-TNF therapies and to explore RIPK1 inhibitors as targeted therapy.
This is promising early translational research, not a new approved treatment; the relevance to broader Crohn's populations and clinical utility will need validation in further studies and clinical trials.
This report summarizes a research study (multi-omics, cellular and animal model work) published in Gastroenterology; it identifies a rare monogenic cause in a small number of families but also suggests broader pathway relevance. Clinical implications depend on replication, broader screening, and results from RIPK1 inhibitor trials.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...
Scientists found BIRC3 gene changes that cause Crohn’s in some patients and showed those changes drive inflammation through the RIPK1/TNF pathway. That suggests a new, druggable pathway and may help predict who benefits...
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
